Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $32.00 price objective on the stock.

Other equities research analysts have also issued research reports about the company. Jefferies Financial Group lifted their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Monday, February 10th. Piper Sandler initiated coverage on Compass Therapeutics in a report on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price target for the company. Guggenheim initiated coverage on Compass Therapeutics in a research note on Monday, February 24th. They issued a “buy” rating and a $12.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.38.

Compass Therapeutics Price Performance

Shares of NASDAQ CMPX opened at $2.24 on Tuesday. The stock has a fifty day moving average price of $2.83 and a 200 day moving average price of $2.11. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $4.08. The company has a market cap of $309.75 million, a PE ratio of -6.05 and a beta of 1.19.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Analysts anticipate that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Several hedge funds have recently bought and sold shares of the company. Enavate Sciences GP LLC purchased a new stake in Compass Therapeutics during the fourth quarter worth $11,293,000. Tang Capital Management LLC boosted its position in shares of Compass Therapeutics by 225.4% in the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock worth $8,555,000 after buying an additional 4,087,005 shares in the last quarter. MPM Bioimpact LLC boosted its position in shares of Compass Therapeutics by 51.9% in the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock worth $12,423,000 after buying an additional 2,926,002 shares in the last quarter. SG Americas Securities LLC grew its stake in Compass Therapeutics by 921.6% in the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock valued at $573,000 after acquiring an additional 356,352 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Compass Therapeutics by 512.5% during the 4th quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company’s stock valued at $395,000 after acquiring an additional 227,864 shares in the last quarter. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.